Download our whitepaper,

Cardiovascular Safety Monitoring:
Protecting Trial Participants

What's Inside:

  • ECG monitoring and QT interval assessment.
  • Cardiovascular adverse event adjudication.
  • Biomarker monitoring for cardiac safety.
  • Independent cardiovascular endpoint committees.
  • Thorough QT studies and regulatory requirements.
  • Risk stratification and patient safety protocols.

Access your complimentary whitepaper today:






    Heart Failure with Reduced Ejection Fraction (HFrEF)

    Heart Failure with Reduced Ejection Fraction (HFrEF) remains a significant global health challenge, affecting millions of patients and placing an increasing burden on healthcare systems worldwide. Despite substantial advances in treatment, morbidity and mortality rates remain high, underscoring the urgent need for innovative therapeutic solutions.

    This whitepaper serves as a comprehensive resource for biotech and pharmaceutical companies, as well as researchers, aiming to develop novel therapies for HFrEF. It provides a detailed analysis of the epidemiology, pathophysiology, and regulatory landscape of HFrEF, alongside insights into pivotal clinical trials and the evolving treatment paradigm.

    Key highlights of this whitepaper include current market landscape, clinical development challenges, regulatory considerations, and opportunities for innovation.

    HFrEF affects approximately

    64

    million people worldwide

    Up to

    25%

    of HFrEF patients are readmitted within 30 days of discharge

    The HFrEF drug market is valued at USD

    $1.1

    billion

    Our clinical team has over

    120

    years of combined clinical trial experience